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CObjectives: Breast cancer poses a huge medical burden to the U.S.
health-care system, and chemotherapy is an important contributor to
cancer costs. This article examines the differences between breast can-
cer patients who received chemotherapy and those who did not in
costs and survival by age, treatment, and axillary node status.
Methods: We studied a cohort of 23,110 node-positive and 31,572
node-negative women aged 65 years and older diagnosed with incident
American Joint Committee on Cancer stage I, II, or IIIA breast cancer
between January 1, 1991, and December 31, 2002, using Surveillance
Epidemiology and End Results–Medicare data. Total treatment costs
and costs associated with the use of chemotherapy were estimated by
using the phase-of-care approach. The phase-specific costs were com-
bined to estimate total Medicare payments for cancer care from diag-
nosis to death. Cox proportional hazard ratio of mortality was used to O
o rep
, and
al So
doi:10.1016/j.jval.2011.10.004etermine the effectiveness of adjuvant chemotherapy after adjusting
or selected patient and tumor characteristics. We used propensity
cores to minimize the bias associated with the receipt of adjuvant
hemotherapy. Results: Regression-adjusted difference in the average
ifetime cost estimates for all node-positive patients receiving chemo-
herapy was approximately $2438 and was significantly higher (P 
.05) than for patients not receiving chemotherapy. Mortality was sig-
ificantly lower in node-positive and node-negative women aged 65 to
4 years receiving chemotherapy. Conclusions: Decision makers can
se cost and effectiveness estimates from this study to assess the rel-
tive value of chemotherapy in different age groups.
eywords: chemotherapy, effectiveness, phase of care, treatment.
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Breast cancer poses a huge medical burden to the U.S. health-care
system, second only to lung cancer as the leading cause of cancer
mortality in women. In addition, the economic burden associated
with breast cancer is considerable. A majority of the studies esti-
mating the costs associated with breast cancer reported the life-
time costs associated with breast cancer care [1–5], ranging from
$50,448 over an average of 9.5 years to $65,036 over a 15-year pe-
riod in women of all ages. More than one-half of new cases and
approximately two-third of all cancer-related deaths occur among
those aged 65 years or older [6]. Much of the breast cancer treat-
ment-related costs have been and will be borne by Medicare be-
cause breast cancer prevalence increases with age. While studies
have evaluated the costs associated with breast cancer treatment,
only a few studies have compared chemotherapy-related costs
among different age groups in the elderly [7,8].
Chemotherapy is an essential component of the cost associ-
ated with breast cancer treatment and is a major factor contribut-
ing to the economic burden associated with breast cancer. Che-
motherapy efficacy and guidelines for its use differ by stage of
tumor and age of the patient [9–17]. According to the National
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Published by Elsevier Inc.Institutes of Health consensus, combination chemotherapy was
recommended for operable pre- and postmenopausal women
aged younger than 70 years and with positive lymph nodes [18,19].
But there are no clear recommendations for adjuvant chemother-
apy in women aged 70 years and older. Lack of data with respect to
elderly patients is the result of exclusion criteria for age in certain
clinical trials and physician bias based on the notion that adjuvant
chemotherapy will not be beneficial to older patients [20–23].
In some randomized clinical trials [17], however, younger and
older women had similar benefits with added chemotherapy in
terms of recurrence reduction and survival. Conversely, meta-
analyses from various clinical trials have revealed that chemo-
therapy benefit decreases with increasing age [9]. Consequently,
there is inconclusive evidence in the literature regarding the ben-
efit of adjuvant chemotherapy in elderly patients.
Elderly patients with comorbidities may have worse survival
due to competing causes of mortality in these patients. Elderly
patients with good health, however, can expect several additional
years of life [24]. This study examines the variation in the cost and
effectiveness of chemotherapy among different age groups in el-
derly patients with early stage breast cancer. Previous studies
have not explicitly examined adjusted cost estimates by axillary
node status and age of the patient. We hypothesize that patients
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advanced stages and higher chemotherapy-related costs, and con-
sequently it is essential to obtain cost estimates by axillary node
status [5,7,8,25]. To our knowledge, this is the first study to exam-
ine the differences in the costs and survival by age, treatment, and
axillary node status.
Methods
Data sources
This study utilized data from the Surveillance Epidemiology and
End Results (SEER)–Medicare linked database for Medicare benefi-
ciaries. The SEER data are a primary source of national data on
cancer incidence and survival and contain information on patient
demographics such as age, race and gender, each occurrence of
primary incident cancer, month and year of diagnosis, type of
surgery performed, stage of disease at diagnosis, using the tumor–
node–metastasis classification from the American Joint Commit-
tee on Cancer, and cause of death. The SEER program includes
population-based tumor registries in 17 geographic areas: San
Francisco/Oakland, Detroit, Seattle, Atlanta, Rural Georgia, Alaska
native, Los Angeles county, the San Jose-Monterey area, and the
rest of California; and the states of Connecticut, Iowa, New Mexico,
Utah, Hawaii, Kentucky, Louisiana, and New Jersey. The four reg-
istries from Kentucky, Louisiana, New Jersey, and greater Califor-
nia became available in 2000, thus increasing the coverage from
14% in 1991 to 1999 to 25% of the U.S. population in 2000 to 2002.
Our analysis did not include Alaska native because of the small
number of cases.
Medicare is a federally funded program and the primary health
insurer for 97% of the elderly U.S. population aged 65 years and
older. Patients with complete coverage of Medicare Part A and Part
B and not members of health maintenance organizations were
included in the study to ensure the completeness of Medicare
claims. The University of Texas Health Science Center at Houston
Committee for Protection of Human Subjects approved the study
protocol.
Study population
The study population consisted of 23,110 node-positive and 31,572
node-negative women aged 65 years and older who were diag-
nosed with incident American Joint Committee on Cancer stage I,
II, or IIIA (early stage operable) breast cancer between January 1,
1991, and December 31, 2002.
Study variables
Treatment factors analyzed in this study included receipt of the
primary surgical treatment, chemotherapy received any time after
diagnosis, and chemotherapy received 6 months after diagnosis.
The primary outcomes assessed were lifetime costs associated
with treatment by age group and mortality due to any cause. In-
formation on the months of survival from the date of diagnosis
was obtained from the SEER data.
Cost
Costs mentioned in this study refer to the amount reimbursed by
Medicare. We used the amount paid by Medicare rather than
charges on the claim as a proxy for the estimation of the direct
medical care costs.
Primary surgery and radiation after breast-conserving surgery
Receipt of the primary surgical treatment was available from the
SEER data. The type of primary surgery was categorized intobreast-conserving surgery (BCS) and mastectomy. Radiation after
BCS was dichotomized into receipt and no receipt categories.
Chemotherapy
Receipt of chemotherapy within 6 months of diagnosis and any-
time after diagnosis was confirmed through Medicare claims. The
identification of chemotherapy through Medicare claims has been
described previously and is reportedly reliable [26]. Chemotherapy
was also dichotomized into receipt and no receipt categories.
Patient characteristics
The following patient characteristics were assessed in the study:
age (65–69 years, 70–74 years, 75–79 years, 80–84 years, and 85 and
older), race (Whites and African Americans), marital status (mar-
ried, unmarried, or unknown), SEER geographic area (SEER re-
gions), year of cancer diagnosis (1991–2002), and socioeconomic
status (quartiles of poverty, with poverty measured at the census-
tract level). The census tract poverty rates were defined as the
percentage of individuals in the tract who are below the federal
poverty line.
Tumor characteristics
The following tumor characteristics were assessed in the study:
tumor stage (American Joint Committee on Cancer stage I, II, or
IIIA), tumor size in cm (1.0, 1.0–1.9, 2.0–2.9, 3.0–3.9,4.0, or miss-
ing), tumor grade (well differentiated, moderately differentiated,
poorly differentiated, or unknown), number of positive lymph
nodes (0, 1, 2–3, 4–5, 6–9, 10–51, or missing), and hormone receptor
status (positive, negative, or unknown).
Comorbidity index
Cormorbidity was determined by using the Medicare claims data
through diagnoses or procedures made 1 year before and 1 month
after breast cancer diagnosis. The comorbidity index was based on
the presence of four common comorbid conditions seen in breast
cancer patients: hypertension, diabetes mellitus, heart disease,
and cerebral vascular accidents. A weighted comorbidity score
was created by using previously reported methods [27] and coded
s 0, 1, and 2.
Data analysis
Estimation of cost
Total treatment costs and costs associated with the use of chemo-
therapy were estimated by using the phase-of-care approach de-
veloped by Riley et al. [4]. This method of evaluating costs associ-
ated with cancer care uses the natural history of the disease and
the corresponding patterns of treatment. The phase-of-care ap-
proach involved distributing the period of treatment from diagno-
sis to death into different phases and then estimating the average
payments for each phase individually. The phases were defined as
the initial care phase, the continuing care phase, and the terminal
care phase. The initial care phase included the first 6 months after
diagnosis and corresponded to the time for diagnostic workup and
the initial course of therapy. The terminal care phase was defined
as the last 6 months of life. The continuing care phase was defined
as the period between the initial and the terminal care phases.
The phase-specific payments were then combined to estimate
the total Medicare payments for cancer patients from diagnosis to
death. The phase distribution used in this study was adapted from
a previous study by Warren et al. [5]. Patients with short-term
survival pose an analytical problem because there may not be ad-
equate months of survival to ascertain full-term initial and termi-
nal care phases. For patients surviving less than 6 months, all the
costs were assigned to the terminal care phase. For patients sur-
viving 12 months or less, the costs were divided into terminal (the
Table 1 – Comparison of characteristics of elderly women with early stage operable breast cancer receiving adjuvant chemotherapy versus those not receiving.
Patient and tumor
characteristics
Comparison in column percentage between patients receiving chemotherapy and those not receiving chemotherapy
Node positive Node negative
Number of
patients
with breast
cancer
Patients not
receiving
chemotherapy
Patients
receiving
chemotherapy
P value* P value after
adjusting for
propensity score†
Number of
patients
with breast
cancer
Patients not
receiving
chemotherapy
Patients
receiving
chemotherapy
P value* P value after
adjusting for
propensity score†
Age (y)
65–69 5053 12.7 41.3 0.001 0.01 9177 25.1 45.6 0.001 0.001
70–74 5652 19.8 30.8 9668 28.4 31.6
75–79 5919 25.4 19.4 8258 25.5 16.6
80–84 4937 24.6 6.8 4692 15.0 4.9
85 3235 17.2 1.5 1752 5.7 1.1
Race
White 21,683 87.8 86.4 0.001 0.94 29,683 89.2 87.4 0.01 0.001
Black 1797 7.1 7.5 1713 4.9 6.3
Others 1316 5.0 5.9 1971 5.8 6.2
Marital status
Married 9623 34.5 50.5 0.001 0.39 15,829 46.3 54.4 0.01 0.01
Unmarried 14,254 61.5 46.4 16,701 50.6 42.6
Unknown 919 3.9 3.0 1017 3.0 2.9
Tumor stage
I 7904 41.8 4.6 0.001 0.01 25,815 79.3 56.9 0.01 0.01
II 15,091 53.0 82.2 7727 20.6 43.0
IIIA 1801 5.1 13.1 5 0.01 0.03
Tumor size (cm)
1.0 3950 19.2 6.8 0.001 0.66 8576 27.5 8.7 0.01 0.01
1.0–2.0 8134 34.7 27.3 14,960 45.2 39.3
2.0–3.0 5892 22.5 27.2 6331 17.5 29.8
3.0–4.0 2810 10.2 14.4 2058 5.3 12.3
4.0 3468 11.6 20.3 1614 4.2 9.6
Unknown size 542 1.6 3.7 8 0.03 0
Number of positive nodes
1 5254 19.1 26.8 0.001 0.01 N/A N/A N/A N/A N/A
2–3 3518 11.0 22.6
4–9 2877 7.3 23.2
10–51 1648 3.7 14.5
Unknown number, but
positive
11,499 58.6 12.6
Tumor grade
Well differentiated 3914 18.2 9.1 .0.001 0.01 7063 22.2 10.7 0.001 0.001
Moderately differentiated 9206 38.0 34.6 13,115 39.9 32.3
Poorly differentiated 7564 25.6 43.8 7966 21.1 45.2
Unknown 4112 18.1 12.3 5403 16.6 11.6
(continued on next page)
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Table 1 (continued)
Patient and tumor
characteristics
Comparison in column percentage between patients receiving chemotherapy and those not receiving chemotherapy
Node positive Node negative
Number of
patients
with breast
cancer
Patients not
receiving
chemotherapy
Patients
receiving
chemotherapy
P value* P value after
adjusting for
propensity score†
Number of
patients
with breast
cancer
Patients not
receiving
chemotherapy
Patients
receiving
chemotherapy
P value* P value after
adjusting for
propensity score†
Hormone receptor status
Positive 17,115 71.0 63.3 0.001 0.03 23,977 73.8 51.7 0.001 0.01
Negative 2896 7.8 22.1 3818 8.6 34.1
Unknown 4785 21.0 14.5 5732 17.4 14.1
Surgery and radiation
BCS alone 6099 28.9 12.5 0.001 0.09 3459 9.9 13 0.001 0.01
BCS with radiation 6660 28.1 23.3 13,070 39.4 35.1
Mastectomy alone 7252 29.7 28. 14,961 45.1 40.2
Mastectomy with
radiation
4096 10.0 34.3 1989 5.2 11.2
Grow factors
Yes 21,377 96.4 58.1 0.001 0.01 31,481 96.9 67.4 0.001 0.001
No 3419 3.5 41.8 2066 3.0 32.5
Comorbidity scores
0 15,842 60.9 71.8 0.001 0.36 23,439 69.4 73.5 0.001 0.001
1 5548 23.2 19.9 6878 20.6 19.0
2 3406 15.7 8.2 3230 9.8 7.4
Household income
First quartile ($27,669) 6281 25.1 25.8 0.01 0.98 8397 24.9 25.9 0.01 0.01
Second quartile ($27,670–
$34,464)
6000 24.3 23.8 8415 25.1 24.3
Third quartile ($34,465–
$43,974)
6018 24.4 23.7 8444 25.3 23.8
Fourth quartile ($43,974) 6149 24.6 25.1 7811 23.1 24.7
Unknown 348 1.3 1.4 480 1.4 1.1
BCS, breast-conserving surgery; N/A, not applicable; SEER, Surveillance, Epidemiology and End Results cancer registry.
* P value generated from the Mantel–Haenszel chi-square statistic.
† P value generated from the Cochrane Mantel–Haenszel chi-square statistic, adjusting for propensity score (categorized into quintiles).
75
V
A
L
U
E
IN
H
E
A
L
T
H
1
5
(2
0
1
2
)
7
2
–
8
0
ey te
76 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 – 8 0last 6 months of treatment) and initial (remainder) care costs. For
patients surviving through the study period, costs were assigned
into initial and continuing care phases. For these patients, pay-
ments for the last year of follow-up (2005) were discarded because
we could not determine whether the costs incurred during 2005
should be assigned to the continuing care phase or the terminal
care phase. Chemotherapy-attributable costs were calculated by
subtracting the costs for patients not receiving chemotherapy
from the costs of those receiving chemotherapy in each age group.
Total costs associated with surgery and radiation were also esti-
mated. Lifetime patient costs associated with breast cancer treat-
ment were calculated as the sum of initial, continuing, and termi-
nal phase care costs. For example, for a patient surviving 4 years,
total patient costs were calculated as the sum of initial (first 6
months), terminal (last 6 months), and 24 months of continuing
care costs. Total treatment costs were evaluated for all patients
accounting for the axillary nodal status of the patient. Medicare
reimbursements were inflated to 2011 U.S. dollars by using the
Consumer Price Index for medical care [28]. Unadjusted costs were
compared between the two groups by using the Wilcoxon–Mann–
Whitney test. Costs were also adjusted by using an ordinary least
squares regression that controlled for patient demographic, treat-
ment, and clinical factors. Because the cost distribution was not
normal, costs were log transformed. To avoid the bias of simple
exponentiation of the predicted log costs, a Duan smearing esti-
mation technique was utilized separately for the two treatment
groups. Long-term costs were estimated without applying a dis-
count rate as well as with a 3% discount rate [29].
Effectiveness of chemotherapy
The method for determining the effectiveness of chemotherapy
was adapted from a previous methodology utilized by Du et al.
[13]. Cox proportional hazard ratio (HR) of mortality was used to
determine the effectiveness of adjuvant chemotherapy after ad-
justing for selected patient and tumor characteristics. To mini-
mize the bias associated with the receipt of adjuvant chemother-
apy, a propensity score analysis was also conducted. Propensity
score is used in observational studies to reduce the bias associated
with the receipt of treatment and is defined as the conditional
probability of being treated given the covariates [30]. A logistic
regression model was used to predict the probability that a patient
receives chemotherapy, given the potential confounding factors
listed in Table 1. The propensity score generated was then divided
into five strata (quintiles) for all patients and stratified for age
groups. It has been estimated that five strata of propensity scores
Table 2 – Unadjusted and adjusted patient costs attributab
Age group (y) Unadjusted cost
difference ($)
Node positive
65–69 14,781*
70–74 12,226*
75–79 13,367*
80–84 17,898*
85 and older 11,979*
Node negative
65–69 13,320*
70–74 12,329*
75–79 9615*
80–84 15,965*
85 and older 11,688*
OLS, ordinary least squares.
* P  0.05 as indicated by the nonparametric Wilcoxon–Mann–Whitnare able to eliminate more than 90% of the unbalanced bias fromconfounding factors between the treated and untreated groups
[31]. Mantel–Haenszel chi-square test was conducted initially to
test for any significant differences in the distribution of confound-
ing factors between the treated and untreated groups. The bal-
ances of confounding factors were then tested again by using the
Cochran Mantel–Haenszel chi-square test, which adjusted for the
propensity score in the five quintiles. The covariates that still sig-
nificantly varied between the chemotherapy-treated and un-
treated groups were adjusted again, with the propensity score in
the Cox proportional hazard models. All data were analyzed by
using the statistical software packages SAS, version 9.2, and Inter-
cooled Stata, version 9.0 [32,33].
Results
Descriptive characteristics
Table 1 shows the percentage of elderly node-positive and node-
negative women with early stage operable breast cancer by vari-
ous patient and tumor characteristics, and the comparison be-
tween patients who received chemotherapy and those who did
not receive chemotherapy in terms of the distribution of these
characteristics, before and after adjusting for the propensity score.
Overall, 17% of women with early stage operable breast cancer
received adjuvant chemotherapy. Only 10% of the node-negative
women received adjuvant chemotherapy compared with 43% of
node-positive operable breast cancer women. The use of adjuvant
chemotherapy decreased significantly by age, from 41% in node-
positive women aged 65 to 69 years to 1.5% in women aged 85
years and older. The distribution of cases between the chemother-
apy-treated and untreated groups varied significantly by the po-
tential confounding factors listed in Table 1. After adjusting for
propensity to receive chemotherapy, the distribution of covariates
was balanced in the treated and untreated groups except for stage,
hormone receptor status, grade, and number of positive lymph
nodes for node-positive patients.
Total patient long-term costs
Table 2 presents the total patient cumulative long-term unad-
justed and adjusted costs by age for women receiving chemother-
apy compared with women who did not receive chemotherapy.
Unadjusted costs reflect the overall burden of chemotherapy-re-
lated resources. In both node-positive and node-negative patients,
costs in the chemotherapy group were significantly higher. The
chemotherapy by age group.
Adjusted cost
difference (OLS) ($)
Adjusted cost difference
discounted at 3% ($)
6635* 4798*
2146* 1532*
2438* 1743*
7580 5519
1984 1420
4344* 3116*
2064* 1483*
4558* 3305*
11,696 8433
6702 4796
st.le todifference in the unadjusted total cost for patients who received
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77V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 – 8 0chemotherapy in contrast with patients not receiving any chemo-
therapy was $16,362; the difference in costs was $17,803 in node-
positive patients and $12,595 in node-negative patients. Results
from the Wilcoxon–Mann–Whitney test indicated significant dif-
ferences in the cost (P  0.01) in the chemotherapy and the
onchemotherapy group within each age group. Results from the
rdinary least squares regression analysis indicated that the che-
otherapy costs for patients aged 65 to 69 years were $6635 in
ode-positive patients and $4798 in node-negative patients. Dif-
erence in the total patient costs in the chemotherapy and
onchemotherapy groups was approximately $2146 among pa-
ients aged 70 to 74 years and $2438 among patients aged 75 to 79
ears. The ordinary least squares regression-adjusted cost esti-
ates were significantly lower than the unadjusted cost estimates.
Surgery- and radiation-associated costs
Table 3 presents the total patient costs in node-positive and node-
negative patients receiving BCS, mastectomy, and radiation. Costs
varied by type of surgery administered, and overall patients in the
group receiving chemotherapy had higher costs than did patients
not undergoing chemotherapy in all age groups. Node-positive pa-
tients undergoing BCS only and mastectomy plus radiation had
higher chemotherapy-attributable costs in the older age groups
(80 years and older).
Total patient costs by phase of care
Table 4 presents the total costs associated with the use of chemo-
therapy by phase of care. Women receiving chemotherapy had
Table 3 – Unadjusted patient costs attributable to chemoth
Treatment  c
65–69 y 70
Node positive
BCS only 2352* 10
BCS with radiation 8058* 1
Mastectomy 1888* 2
Mastectomy with radiation 673 5
Node negative
BCS only 6340* 7
BCS with radiation 6728* 2
Mastectomy 3343 3
Mastectomy with radiation 7615
BCS, breast-conserving surgery.
* P  0.05 as indicated by the nonparametric Wilcoxon–Mann–Whitn
Table 4 – Unadjusted patient costs attributable to
chemotherapy by age group and phase of care.
Phase Age group (y)
65–69 70–74 75–79 80–84 85 and older
Node positive
Initial $5988* $5701* $5295* $4782* $2455*
Continuing $5462* $3325* $5700* $9373* $7233*
Terminal $2896* $2168* $2904* $4301* $1049
Node negative
Initial $3867* $2329* $1899* $1355* $883*
Continuing $5560* $7468* $4984* $11,031* $6462
Terminal $3620* $2281* $2707* $7477* $6169*
* P  0.05 as indicated by the nonparametric Wilcoxon–Mann–g
Whitney test.higher costs than did women who did not receive chemotherapy,
and the differences varied by phase and age group. For example,
the difference in the initial care phase costs between the chemo-
therapy and the nonchemotherapy groups ranged from $2455 to
$5988 among node-positive patients. With chemotherapy admin-
istered for recurrences or during the terminal phase, the unad-
justed difference in the total costs between the chemotherapy and
the nonchemotherapy groups did not vary much among age
groups. Among node-negative patients, the difference in the ini-
tial care phase costs between the chemotherapy and the nonche-
motherapy groups ranged from $883 to $3867 whereas in the con-
tinuing care phase the difference between the two groups ranged
from $4,984 to $11,031 within the different age groups.
Treatment costs by survival experience
Table 5 describes the difference in the total patient costs among
the chemotherapy and the nonchemotherapy group by survival
experience of the patient. For example, chemotherapy-attribut-
able costs ranged from $1,495 to $17,048 for patients surviving less
than 6 months. As seen previously among patients with different
survival experiences, patients in the oldest age groups not receiv-
ing chemotherapy incurred the lowest cost in each phase.
Effectiveness of chemotherapy
Table 6 presents the HR for the mortality associated with receipt of
chemotherapy for all elderly patients with breast cancer and strat-
ified by axillary node status and for the five age groups. HR was
statistically significantly reduced in node-positive women aged 65
to 69 years who received adjuvant chemotherapy compared with
those who did not receive chemotherapy (HR  0.66; 95% confi-
ence interval [CI] 0.58–0.74) and in patients aged 70 to 74 years
HR  0.66; 95% CI  0.59–0.74), after adjusting for all the factors
hat might affect survival. HR was also statistically significantly
educed in patients aged 75 to 79 and 80 to 84 years; however, the
trength of association decreased with increasing age. For women
ged 85 years and older, the HR did not significantly differ between
he treated and the untreated groups. In node-negative patients,
he HR was statistically significantly reduced only in women aged
5 to 69 years (HR 0.78; CI 0.67–0.91) and in women aged 70 to
4 years (HR  0.78; CI  0.65–0.88). In all other age groups, che-
otherapy did not have a significant effect on the mortality.
The effect of chemotherapy on mortality was also evaluated by
djusting for propensity score. The covariates (age, stage, grade,
ormone receptor status, and number of positive lymph nodes)
hat remained unbalanced between the treated and untreated
y by age group and treatment.
(chemotherapy – no chemotherapy) ($)
75–79 y 80–84 y 85–89 y
938* 25,427* 11,656
9111* 9905* 1431
147* 11,017* 10,995
10,258* 13,130* 15,384
8592* 14,968* 11,155
3296* 7835 577
3970* 15,238* 11,797
5506 21,273 22,374
st.erap
osts
–74 y
,056*
105*
008*
279*
997*
193*
440
303roups as shown in Table 1 were adjusted together with propen-
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78 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 – 8 0sity score in the analysis. Mortality was still significantly reduced
in node-positive women even after adjustment for propensity in
women aged 65 to 69 years (HR  0.61; CI  0.54–0.68) and in
omen aged 70 to 74 years (HR 0.64; CI 0.57–0.71) who received
Table 5 – Unadjusted patient costs attributable to chemoth
Phase
Patients surviving less than 6 mo
Terminal
Patients surviving less than 1 y
Initial
Terminal
Patients surviving more than 1 y but dead as of Medicare DOD
Initial
Continuing
Terminal
Patients alive as of Medicare date December 31, 2005
Initial
Continuing
DOD, date of death.
Table 6 – Effect of adjuvant chemotherapy on mortality
in node-positive elderly women with early stage
operable breast cancer.
Age group (y) Total number of
patients (% of
patients
receiving
adjuvant
chemotherapy)
Risk (Cox proportional
HR and 95% CI)*
HR 95% CI
Node positive
65–69 5053 (54.2) 0.66† 0.58–0.74
70–74 5652 (36.1) 0.66† 0.59–0.74
75–79 5919 (21.7) 0.87† 0.78–0.97
80–84 4937 (9.2) 0.81† 0.70–0.94
85 3235 (3.1) 0.83 0.64–1.06
Node negative
65–69 9177 (17.7) 0.78† 0.67–0.91
70–74 9668 (11.6) 0.76† 0.65–0.88
75–79 8258 (7.1) 0.91 0.77–1.07
80–84 4692 (3.7) 0.85 0.67–1.08
85 1752 (2.3) 0.89 0.58–1.34
Significant at P  0.05.
BCS, breast conserving surgery; CI, confidence interval; HR, hazard
ratio; SEER, Surveillance, Epidemiology and End Results cancer reg-
istry.
* Cases who received adjuvant chemotherapy versus those who
did not.
† Cox proportional HR was adjusted for race (white, black, other),
marital status (married, unmarried, unknown), tumor stage (I, II,
IIIA), tumor size (1, 1 to2, 2 to3, 3 to4,4cm, or unknown),
grow factors (yes, no), hormone receptor status (positive, nega-
tive, or unknown), tumor grade (well, moderately or poorly differ-
entiated, or undetermined), number of positive lymph nodes (1,
2–3, 4–9, 10–51, and positive nodes but unknown number), co-
morbidity index scores (0, 1, 2, or 3), 12 SEER areas, treatment
given (BCS only, BCS plus radiotherapy, mastectomy alone, or
mastectomy with radiation), census tract household income, andyear of diagnosis.hemotherapy compared with those who did not receive chemo-
herapy. HR was also significantly reduced in patients aged 75 to 79
nd 80 to 84 years; however, the strength of association was very
ow. In patients aged 85 years and older, chemotherapy did not
ave a significant effect on mortality.
Discussion
The study examined the economic and clinical outcomes associ-
ated with adjuvant chemotherapy in elderly patients with early
stage operable breast cancer. The study results demonstrated that
total treatment costs in elderly breast cancer patients differ by age
and administration of chemotherapy. Several other studies have
provided long-term estimates of total and phase-specific costs as-
sociated with breast cancer care by stage and treatment adminis-
tered [1,8]. But these studies have not estimated the total costs for
elderly patients receiving chemotherapy by age and axillary node
status of the patient. The current study provides phase-specific
and long-term costs of breast cancer care by age and axillary node
status for fee-for-service Medicare beneficiaries.
Receipt of chemotherapy was an important determinant of
cost across all phases. Costs varied by phase and axillary node
status, which could possibly be a reflection of the difference in the
intensity of chemotherapy administration by phase. Node-posi-
tive patients in each age group undergoing chemotherapy treat-
ment incurred significantly higher costs than did node-negative
patients receiving chemotherapy. By using the SEER-Medicare
data, Warren et al. estimated the mean total monthly chemother-
apy-related costs to be $2321 in comparison to $1648 in patients
not treated with chemotherapy. Total initial care phase costs at-
tributable to the use of chemotherapy were estimated to be ap-
proximately $8000 [5]. In our study, the total regression-adjusted
cost estimate for all node-positive patients receiving chemother-
apy was approximately $2438 (2011 inflated dollars, discounted at
a 3% rate) and was significantly higher than for patients not re-
ceiving chemotherapy.
In the literature, treatment with adjuvant chemotherapy has
been shown to reduce the risk of breast cancer recurrence and
improve the long-term, relapse-free, and overall rate of survival in
both pre- and postmenopausal women with node-positive and
node-negative early stage breast cancer [18,19,34]. Meta-analysis
of all randomized trials on early breast cancer conducted by the
Early Breast Cancer Trialist’s Collaborative Group also reported
that several months of combination chemotherapy in early stage
y by age group and survival.
Age group (y)
69 70–74 75–79 80–84 85 and older
95 $8496 $3706 $13,142 $17,048
53 $3966 $1316 $2197 $1484
05 $7058 $5456 $8440 $3439
68 $2364 $2961 $2552 $1911
58 $2897 $2363 $9708 $6228
27 $2085 $2643 $5123 $2155
79 $5414 $4697 $4359 $1863
83 $5398 $6959 $9331 $8041erap
65–
$14
$29
$98
$14
$26
$30
$64
$38breast cancer offered a significantly high relative reduction in
79V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 7 2 – 8 0mortality [9,10]. But the absolute reduction in survival in node-
negative patients was found to be lesser than in node-positive
patients. Results from the current study indicate the benefit of
chemotherapy in node-positive and node-negative patients aged
65 to 74 years, but the evidence that adjuvant chemotherapy re-
duces the risk of mortality for patients aged 75 years and older is
not strong. Age is a significant predictor in determining the admin-
istration of chemotherapy due to concerns regarding toxicity and
comorbidity [20,35–38]. Elderly patients typically suffer from co-
morbidities not related to cancer and poorer functional status at
diagnosis than do younger patients with similar level of disease.
Women who received chemotherapy had worse prognostic indica-
tors than did those who did not receive chemotherapy. These indi-
cators could have led to a bias, but the differential distribution of
these factors in the treated and untreated groups was minimized by
using propensity score analysis, though some factors not linked to
the measured confounders may be affecting these results.
We found that in node-positive and node-negative women
aged 65 to 74 years and in node-positive women aged 75 to 79
years, chemotherapy increased costs and reduced mortality. In
node-positive women aged 80 to 84 years, chemotherapy did not
increase costs but improved survival, while in node-negative
women aged 75 to 79 years, chemotherapy increased costs with-
out improving survival.
Major strengths of this study include population-based longi-
tudinal data, large sample size, and adjustment for potential con-
founders that may influence treatment decisions. Total patient
costs were adjusted for patient demographic, clinical, and comor-
bidity levels, which affect and contribute to total treatment costs.
To minimize the bias associated with the receipt of adjuvant che-
motherapy, we also conducted a propensity score analysis. A pos-
sible limitation of our approach is that we included surgery and
radiation in the propensity score to control for initial treatment,
though surgery and radiation decisions may well be influenced by
the decision of whether or not to undergo chemotherapy. The
study results should be interpreted with caution. First, we did not
have data on adjuvant hormone therapy (tamoxifen) that may be
administered with chemotherapy if the patient is estrogen recep-
tor/progesterone receptor positive. Also, we did not include de-
tailed information about the chemotherapy regimens and adverse
events related to chemotherapy because it would have been be-
yond the scope of this article. Second, because we were interested
in the total costs associated with chemotherapy, we assumed that
costs not related to cancer were similarly distributed in the two
groups; hence, a control group was not utilized in this study. Third,
there was also no information on the education level of the pa-
tient, which has been shown previously to impact breast cancer
treatment decisions. The socioeconomic status indicators were
available only at the census-tract level and not at an individual
level, which may introduce residual confounding. Fourth, data on
other factors such as patient and physician preferences, quality-
adjusted survival measures, distance to cancer center, access to
specialized providers, and so on that may affect the administra-
tion of chemotherapy was not available. Fifth, the study popula-
tion was limited to non–health maintenance organization Medi-
care enrollees aged 65 years and older; therefore, the current
findings may not be generalizable to other populations and in
younger age groups. Finally, we analyzed data from 1991 to 2002,
the most recent data available for this type of investigation at the
time of the study, and treatment patterns have changed over the
last decades. Future research should explore whether findings are
similar in more recently diagnosed cases with more recent data as
they become available. We believe that, however, till more recent
and comprehensive data are investigated, our findings provide
detailed and valuable information on costs and relative resource
use in this group of elderly breast cancer patients. As the survival
time for women with breast cancer will increase, the long-termcosts associated with chemotherapy will increase because of lon-
ger continuing care phases. Changes in treatment regimens and
advancements in new pharmacological treatments may also im-
pact the overall survival and total costs. Although our analysis
should be considered exploratory because of the lack of detailed clin-
ical records, we conclude that chemotherapy is associated with in-
creased survival among patients with node-positive tumors aged 65
to 74 years and is associated with higher total patient costs.
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